ATE485818T1 - Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren - Google Patents
Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumorenInfo
- Publication number
- ATE485818T1 ATE485818T1 AT03772067T AT03772067T ATE485818T1 AT E485818 T1 ATE485818 T1 AT E485818T1 AT 03772067 T AT03772067 T AT 03772067T AT 03772067 T AT03772067 T AT 03772067T AT E485818 T1 ATE485818 T1 AT E485818T1
- Authority
- AT
- Austria
- Prior art keywords
- cholesterol
- ezetimibe
- associated tumor
- methods
- malignant tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39969002P | 2002-07-30 | 2002-07-30 | |
US10/630,578 US6933292B2 (en) | 2002-07-30 | 2003-07-30 | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
PCT/US2003/023764 WO2004010948A2 (en) | 2002-07-30 | 2003-07-30 | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE485818T1 true ATE485818T1 (de) | 2010-11-15 |
Family
ID=32511171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03772067T ATE485818T1 (de) | 2002-07-30 | 2003-07-30 | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren |
Country Status (10)
Country | Link |
---|---|
US (3) | US6933292B2 (de) |
EP (1) | EP1545479B1 (de) |
JP (1) | JP2006501205A (de) |
CN (1) | CN1678296A (de) |
AT (1) | ATE485818T1 (de) |
AU (1) | AU2003254261B2 (de) |
CA (1) | CA2493614C (de) |
DE (1) | DE60334711D1 (de) |
NZ (1) | NZ538498A (de) |
WO (1) | WO2004010948A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
EP1545479B1 (de) * | 2002-07-30 | 2010-10-27 | Karykion Inc. | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren |
CA2540364A1 (en) * | 2003-09-26 | 2005-04-07 | Forbes Medi-Tech Inc. | Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
WO2006107936A1 (en) * | 2005-04-04 | 2006-10-12 | Pontificia Universidad Catolica De Chile | The use of ezetimibe in the prevention and treatment of cholesterol gallstones |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
US20090208448A1 (en) * | 2008-02-15 | 2009-08-20 | Solomon Keith R | Inhibition of angiogenesis |
EP2337570A4 (de) * | 2008-09-02 | 2012-03-28 | Univ Illinois | Zusammensetzungen und verfahren zur hemmung des eintritts eines hepatischen virus |
US9034863B2 (en) | 2008-09-02 | 2015-05-19 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for inhibiting entry of a hepatic virus |
WO2015065505A1 (en) * | 2013-10-29 | 2015-05-07 | Duke University | Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer |
BR112022009066A2 (pt) * | 2019-11-12 | 2022-08-09 | Univ South Africa | Ezetimiba para uso em tratamento de câncer |
WO2022087437A1 (en) * | 2020-10-22 | 2022-04-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods of treatment |
CN115364094A (zh) * | 2021-05-19 | 2022-11-22 | 南京大学 | 伊折麦布在制备抗肿瘤药物中的应用 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637389A (de) * | 1962-09-13 | |||
US3622437A (en) * | 1969-05-09 | 1971-11-23 | Gen Dynamics Corp | Composite buoyancy material |
EP0002097B1 (de) * | 1977-08-22 | 1981-08-05 | Imperial Chemical Industries Plc | Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten |
DE3046719C2 (de) * | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4719207A (en) * | 1984-06-25 | 1988-01-12 | Yamanouchi Pharmaceutical Co., Ltd. | CNS active substituted azetidinone compounds |
US4639420A (en) * | 1984-11-21 | 1987-01-27 | Schaffner Carl P | Method for the immunoanalysis of cholesterol epoxides |
EP0260066B1 (de) * | 1986-09-11 | 1990-05-09 | National Research Development Corporation | Tamoxifenderivate |
DE69034035T2 (de) * | 1989-07-07 | 2004-01-22 | Endorecherche Inc., Ste-Foy | Methode zur behandlung androgenbedingter krankheiten |
EP0524595A1 (de) * | 1991-07-23 | 1993-01-27 | Schering Corporation | Substituierte Beta-Lactam-Verbindungen als Hypocholesterolemische Mittel und Verfahren zu deren Herstellung |
AU680818B2 (en) * | 1992-05-21 | 1997-08-14 | Endorecherche Inc. | Improved antiandrogens |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5972383A (en) * | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5613460A (en) * | 1994-08-31 | 1997-03-25 | Newport News Shipbuilding And Dry Dock Company | Submersible vessel external load mounting system |
US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
JPH10179086A (ja) * | 1996-11-05 | 1998-07-07 | Riken Vitamin Co Ltd | 植物ステロールを含有する油溶化液及び飲食物並びにその製造方法 |
US6245352B1 (en) * | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
US6380405B1 (en) * | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
EP1259237A4 (de) * | 2000-02-17 | 2004-07-28 | Merck & Co Inc | Behandlung und prophylaxe des prostatakrebs mit cox-2 selektiven inhibitoren |
US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
CA2421018A1 (en) * | 2000-09-06 | 2002-03-14 | Merck & Co., Inc. | Dihydroxy open-acid salt of simvastatin |
WO2002026729A2 (en) | 2000-09-27 | 2002-04-04 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
US6534540B2 (en) * | 2000-10-06 | 2003-03-18 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor |
IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
PL209375B1 (pl) * | 2000-12-28 | 2011-08-31 | Kissei Pharmaceutical | Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej |
EP1859796A3 (de) | 2001-09-21 | 2008-07-02 | Schering Corporation | Behandlung von xanthom mit azetidinon-derivaten als hemmer der sterol absorption |
EP1545479B1 (de) * | 2002-07-30 | 2010-10-27 | Karykion Inc. | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren |
US20040145092A1 (en) * | 2003-01-24 | 2004-07-29 | Mccollum Robert P. | Method of making a composite molded article |
US7263028B2 (en) * | 2003-10-09 | 2007-08-28 | United States Of America As Represented By The Secretary Of The Navy | Composite acoustic attenuation materials |
-
2003
- 2003-07-30 EP EP03772067A patent/EP1545479B1/de not_active Expired - Lifetime
- 2003-07-30 US US10/630,578 patent/US6933292B2/en not_active Expired - Lifetime
- 2003-07-30 AU AU2003254261A patent/AU2003254261B2/en not_active Ceased
- 2003-07-30 DE DE60334711T patent/DE60334711D1/de not_active Expired - Lifetime
- 2003-07-30 CN CNA038205904A patent/CN1678296A/zh active Pending
- 2003-07-30 JP JP2004525042A patent/JP2006501205A/ja active Pending
- 2003-07-30 NZ NZ538498A patent/NZ538498A/en not_active IP Right Cessation
- 2003-07-30 WO PCT/US2003/023764 patent/WO2004010948A2/en active Application Filing
- 2003-07-30 AT AT03772067T patent/ATE485818T1/de not_active IP Right Cessation
- 2003-07-30 CA CA2493614A patent/CA2493614C/en not_active Expired - Lifetime
-
2005
- 2005-05-12 US US11/128,140 patent/US7098198B2/en not_active Expired - Fee Related
-
2006
- 2006-07-13 US US11/485,773 patent/US7449453B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2006501205A (ja) | 2006-01-12 |
DE60334711D1 (de) | 2010-12-09 |
US6933292B2 (en) | 2005-08-23 |
AU2003254261B2 (en) | 2008-04-17 |
US7449453B2 (en) | 2008-11-11 |
WO2004010948A2 (en) | 2004-02-05 |
US20050209167A1 (en) | 2005-09-22 |
EP1545479B1 (de) | 2010-10-27 |
US20070037755A1 (en) | 2007-02-15 |
US7098198B2 (en) | 2006-08-29 |
CA2493614A1 (en) | 2004-02-05 |
WO2004010948A3 (en) | 2004-07-01 |
US20040116358A1 (en) | 2004-06-17 |
CN1678296A (zh) | 2005-10-05 |
NZ538498A (en) | 2009-02-28 |
EP1545479A2 (de) | 2005-06-29 |
AU2003254261A1 (en) | 2004-02-16 |
CA2493614C (en) | 2011-09-13 |
EP1545479A4 (de) | 2007-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE485818T1 (de) | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren | |
DE60031268D1 (de) | Verfahren und zusammansetzung zur behandlung von krebs | |
BR0109517A (pt) | métodos e composições sinérgicas para tratar o cáncer | |
YU59103A (sh) | Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije | |
ATE268179T1 (de) | Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
DE69127175T2 (de) | Antisens-Oligonukleotide zur Behandlung von Krebs | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
RS49756B (sr) | Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija | |
DE602004025726D1 (de) | Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). | |
EA200000282A1 (ru) | Способ введения таксана пациенту, нуждающемуся в лечении таксаном, способ лечения человека таксаном (варианты) | |
ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
ATE260282T1 (de) | Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen | |
ATE170077T1 (de) | Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff | |
DE60121440D1 (de) | Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält | |
EP1427418A4 (de) | Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel und behandlungsverfahren | |
ATE415965T1 (de) | Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung | |
DE59508366D1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
ATE251911T1 (de) | Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten | |
GB2331926A (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
ATE315387T1 (de) | Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz | |
TWI262791B (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
ATE320797T1 (de) | Verwendung von 6-dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz | |
BR0211436A (pt) | Método e composição para tratamento de câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |